ASMD management relies on supportive care in the absence of an approved, disease-modifying therapy.11 Enzyme replacement therapy (ERT) with olipudase alfa (recombinant human ASM, which does not cross the blood–brain barrier) is in clinical development to treat non–central nervous system manifestations of ASMD. Here, SMPD1 is linked to anterior segment dysgenesis.